Search company, investor...
ADARx Pharmaceuticals company logo

ADARx Pharmaceuticals

adarx.com

Founded Year

2019

Stage

Series C | Alive

Total Raised

$352.5M

Last Raised

$200M | 4 mos ago

About ADARx Pharmaceuticals

ADARx Pharmaceuticals is a genetic medicine company focused on the base editing of messenger Ribonucleic Acid (mRNA) transcripts. ADARx Pharmaceuticals discovers and develops therapeutics that utilize a family of endogenous enzymes called adenosine deaminase acting on RNA to target and correct single-point mutations on an mRNA, allowing the production of desired and functional proteins to be restored. It was founded in 2019 and is based in San Diego, California.

Headquarters Location

5871 Oberlin Drive Suite 200

San Diego, California, 92121,

United States

877 232-7974

Loading...

Loading...

ADARx Pharmaceuticals Patents

ADARx Pharmaceuticals has filed 2 patents.

The 3 most popular patent topics include:

  • clusters of differentiation
  • coagulation system
  • coagulopathies
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/30/2022

Coagulation system, EC 3.4.21, Clusters of differentiation, G protein coupled receptors, Coagulopathies

Application

Application Date

9/30/2022

Grant Date

Title

Related Topics

Coagulation system, EC 3.4.21, Clusters of differentiation, G protein coupled receptors, Coagulopathies

Status

Application

Latest ADARx Pharmaceuticals News

The biggest private biotech investments in August 2023

Sep 4, 2023

Image/Anastasiia Slynko The companies Genesis Therapeutics, ADARx Pharmaceuticals, and Abcuro bagged the biggest biotech investments in August 2023. Around the world, companies focused on immunology, genetic disorders, and metabolic disorders attracted the biggest funding rounds. Overall, quite a lot of biotech fundraising took place in August 2023. As always, there were some big rounds within the U.S. healthcare space, and, in Europe, U.K.-based companies dominated the top funding rounds, both in healthcare and outside of healthcare. We’ve gathered the biggest biotech investments that went to private companies around the world in August. The fundraising companies have been split into healthcare and industrial biotechnology-focused verticals. Healthcare investments in August 2023 The U.S.’ top private biotech healthcare investments went to Genesis Therapeutics and ADARx Pharmaceuticals, which both raised $200 million each. Genesis Therapeutics’ Series B round will enable the company to bring its pipeline into clinical development, further advance its AI platform, and expand its discovery pipeline. Meanwhile, the $200 million raised by ADARx Pharmaceuticals in its Series C round will help the company advance its two lead assets into the clinic. The top European biotech healthcare investment round went to Actimed Therapeutics, which secured an additional $6 million funding in a Series A extension round. The proceeds will allow the company to fund its continued development, and ensure preparations for its program evaluating its lead asset for treating cachexia remain on track. Chinese gene therapy company Neurophth Therapeutics topped the healthcare biotech investment list in the Asia-Pacific region, with a $95 million Series C+ investment in August 2023. The funds will be directed towards advancing clinical trials, enhancing the company’s R&D capabilities, and expanding its pipeline. Other life sciences investments in August 2023 Outside of the healthcare sector, many biotech companies managed to raise big investments in August 2023, to advance technologies related to food, sustainability and lab tools. In the U.S., the biggest investment round outside of the healthcare sector went to Newlight Technologies, which bagged $125 million in private equity. The firm is developing decarbonization technology using natural microorganisms to convert greenhouse gases into high-performance AirCarbon-based materials. Meanwhile, U.K.-based life sciences tools company, Lightcast Discovery, had the biggest investment round in Europe, raising $49 million in a Series B round. The firm is developing a novel single-cell functional analysis platform. DP Technology came first place in the Asia-Pacific region, after raising $100 million in private equity. The firm is applying AI technology in the research and development in fields such as biomedicine, energy, materials, and information science and engineering. September’s highlights There haven’t been too many funding rounds yet in September; the most notable one so far has gone to Innovac Therapeutics, which is an mRNA therapeutics company. It managed to raise $18 million in a Series Pre-A financing round, which will allow the company to further develop its technology platform and manufacturing capability to advance its lead programs to clinical stage.

ADARx Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was ADARx Pharmaceuticals founded?

    ADARx Pharmaceuticals was founded in 2019.

  • Where is ADARx Pharmaceuticals's headquarters?

    ADARx Pharmaceuticals's headquarters is located at 5871 Oberlin Drive, San Diego.

  • What is ADARx Pharmaceuticals's latest funding round?

    ADARx Pharmaceuticals's latest funding round is Series C.

  • How much did ADARx Pharmaceuticals raise?

    ADARx Pharmaceuticals raised a total of $352.5M.

  • Who are the investors of ADARx Pharmaceuticals?

    Investors of ADARx Pharmaceuticals include OrbiMed Advisors, SR One, Lilly Asia Ventures, Ascenta Capital, Invus Group and 14 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.